Company intelligence / Profile preview

ITODYS

Watertown, Massachusetts, United Statesitodys.univ-paris-diderot.fr ↗

Ownership: Private
Employees: ~173
Development stage: Other

Overview

iTeos Therapeutics is advancing a pipeline of immuno-oncology therapeutics targeting novel immune pathways in cancer. Lead programs include belrestotug (anti-TIGIT antibody), inupadenant (A2AR antagonist), EOS-984 (ENT1 inhibitor), and EOS-215 (anti-TREM2 antibody). Clinical results are ongoing; belrestotug and inupadenant are among the most advanced assets[5][6].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Notable partnership with GSK for TIGIT program development[6]. Additional collaborations possible but not detailed.

Beyond the preview

Go deeper on ITODYS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITODYS.

Explore the full profile